

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011

Wednesday, October 20, 2021 – 12:00 PM – 1:30 PM

Present: Meghan McNelly, PharmD, MHA; FACHE, Michelle Bennett, RPh, Debbie Rose (Participant Advisory), Germaine Biksey, Jill Schaeffer, RN, Dr. Mahmood Usman, Dr. Kolin Good, Dr. Christopher Hughes, Dr. Keith Brown,

Absent:

Guests: William Baker (Pharmacy), Christina Kauffman (Pharmacy), Amy Nowacki (Pharmacy), Tanayja Sams (Pharmacy), Jason Skaria (Pharmacy Manager), Shalyn Kline (Pharmacy), George Kimbrow, Jr. (PHW Policy Coordinator), Marci Kramer (QI Director), Heather Clarke, (Program Director and Behavioral Health Liaison), Jacci Rowe (Director, Compliance), Shirley Stahler

Call to Order: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:03 PM.

Adjourned: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:22 PM.

Next Meeting: Wednesday, January 19, 2022 – 12:00 PM

Submitted By: William Baker (PHW Pharmacy)

Date: 1/19/2022

Committee Chair: _____ Shalyn Kline, PharmD _____

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:03 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	None			Meghan McNelly
B. Announcements	<p>Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p>	No action required or taken.		Meghan McNelly
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> i. Voting and vote totals ii. Tie breaker iii. Pennsylvania's Review and Approval Process 	No action required or taken.		Meghan McNelly
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q3_2021. No objections were made.	Adoption of Q3_2021 Meeting Minutes recorded as approved		Bill Baker
III. Old Business				

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

A. Policy Submission Status	There is one outstanding clinical policy that is awaiting approval.	No action required or taken.		Bill Baker/Meghan McNelly
New Business				
A. Statewide PDL updates	<p>According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.</p> <p>For quarter three 2021, no PDL modifications have been made. The state will issue a new PDL that will go into effect on January 1, 2022.</p>			Meghan McNelly
B. Schizophrenia provider Education	Voting members were asked if there were any objections to the education. No opposition was expressed.	The education was Committee approved.		Bill Baker
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Bill Baker
D. Drug Coverage Criteria	<p>There were no policy changes by the state.</p> <p>Bill asked the Committee if anyone had issues with the any of the supplemental drug list changes. There were no issues addressed.</p> <p>The Committee was asked if they had any issues with the Ambetter policy changes. There were no issues addressed.</p>	The policy revisions were Committee approved.		Bill Baker
E. Complaints and Grievances Review	Meghan told the Committee that the State requires a 24-hour turnaround time, which does not always allow for outreach. The ruling can be overturned when a grievance is filed. A total of 14			Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	<p>determinations were made in Q3. One was affirmed, nine were overturned, and four were withdrawn pre-grievance.</p> <p>Shalyn Kline has designed fax forms to send to the providers that address specific criteria to help the provider be clearer in their response for a prior authorization.</p> <p>There were five recurring Opioids identified.</p>			
<p>F. PBM Oversight</p>	<p>In Q3, there were 120 requests audited. (60 approvals, 60 denials).</p> <p>Findings for the denials were three requests had the wrong policy utilized, three requests missed the turn-around time because of Envolve staffing, the RxAdvance Fax System, and three Member letters had a readability greater than a 6th grade reading level.</p> <p>Coaching was completed with the Envolve clinical reviewers to address the issues.</p>			<p>Jason Skaria</p>
<p>G. Medicare Pharmacy Updates</p>	<p>Christina presented the Quality Measures for Medicare Part D.</p> <ul style="list-style-type: none"> • Statin use in Patients with ASCVD – 89% compliant. • Statin use in Patients with Diabetes – 86% compliant. • Patient Medication Adherence – Three classes of medication. <ul style="list-style-type: none"> - RAS antagonist adherence – 91% - Diabetes medication adherence – 90% - Statin adherence – 90% • Complaints and Grievances <ul style="list-style-type: none"> - 12 grievances were files for Q3. - 12 Resolved. • Pharmacy Triage – Inquiries including drug information, prior authorization questions, medication reviews, polypharmacy, adverse drug reactions, drug-drug interactions, etc. <ul style="list-style-type: none"> - Q3 Technician inquiries – 42 - Pharmacist inquiries - 30 			<p>Christina Kauffman</p>

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

	<ul style="list-style-type: none"> • FWA <ul style="list-style-type: none"> - Morphine Milligram Equivalent cutoff: 28 Participants were reviewed and no issues were identified. - Multiple opioid prescribers: No Participants identified with three or more practices/hospitals for the quarter. • Inappropriate prescribing <ul style="list-style-type: none"> - No Participants were identified potentially using >4 gm/day of Acetaminophen overutilization. - Nine repeat Participant's were identified being on antipsychotics with an inferred dementia diagnosis. • Disease management <ul style="list-style-type: none"> - There were 19 Participants indented using long-acting beta-agonist monotherapy. All were reviewed. - Faxes were sent to providers for asthma with overuse rescue inhaler. 			
I. COVID 19 Response	<p>Continuing point-of-sale edits for “refill too soon”. Continuing quantity limits for hydroxychloroquine for members without a valid non-COVID – related diagnosis, and late refill reporting. The late refill reporting is sent to the Service Coordinators.</p> <p>Vaccine Clinics are being held.</p>	No action required or taken.		Meghan McNelly
J. Help Wanted	<ul style="list-style-type: none"> • Participant member wanted to join the Committee so we can get their input on how we can be better with CHC. 			
K. Open Forum	Nothing discussed.	No action required or taken.		Meghan McNelly
Adjournment	The meeting was adjourned at 12:22 pm	Meeting adjourned		Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).